Dr. Bhave on Promising Combination Strategies in TNBC

Manali Bhave, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, medical oncologist, Winship Cancer Institute, discusses promising combination strategies in triple-negative breast cancer (TNBC).

Scientific rationale suggests that adding targeted therapies to immunotherapy could enhance neoantigen expression and enhance the efficacy of immunotherapy in patients with TNBC, says Bhave.

Moreover, combinations of targeted therapy and immunotherapy may yield less toxicity vs chemotherapy and could, improve quality of life for this patient population, concludes Bhave.